Well, this is a sticky wicket! SIGA Technologies (which I last wrote about here) has just secured $8 million in financing from MacAndrews & Forbes.
I guess this is good news, because:
1. They say some of it will help fuel development of their product pipeline - and I'm concerned about their really promising stuff moving forward as they fight hard to commercialize ST-246, their lead drug for smallpox.
2. MacAndrews & Forbes get a very large options deal, which means they're pretty confident SIGA is poised for a major run-up (and the press release indicates that M&F has a place on SIGA's board, so they're privy to the latest issues with the hopefully impending $100M order of ST-246).
But it may be bad news, because:
1. SIGA needs to demonstrate their ability to manufacture quantity of ST-246 if they're going to get the aforementioned order contract. Back in April, they hit a snag in this step and hit up the government for more dough. So perhaps things have grown desperate...in which case this $8M isn't going to buy much.
2. This deal may dilute the stock (I don't know enough about finance to understand the impact).
Subscribe to:
Post Comments (Atom)
Blog Archive
-
▼
2008
(190)
-
▼
June
(21)
- Scientist Tastes Silence
- Les Blank's New Film
- Belonging
- The Joys of Full Fare Coach
- Getting Off Friends' Mailing Lists
- Where's All the Aliens?
- News About SIGA
- Journalism Balance Award Goes To....USATODAY???
- Insanity Versus Revelation
- No One Loves You Like a Hater Does
- Smart Phone Lookups Page
- Benny Lava
- Everybody Hates Somebody Sometime
- Home Fries Are Good Again
- Consumer Research Sites
- Get Rich Slow with SIGA
- Deslogging
- Hillary, Sexism, OJ, and an Apology to the Right Wing
- Liz Clark and The Voyage of Swell
- Milton Resnick: Ecstasy Made Visible
- How to pick out shill-reviewed places on Trip Advisor
-
▼
June
(21)
4 comments:
Ask the Banker Wanker!
interesting deal.
but it has the potential to be massively dilutive. consider that the stock falls to $2 for arguments sake - then the mkt cap becomes $68 million and the $8 million becomes a stake of over 10% of the company.
it looks like the company is burning about $8 million a year on an operating basis, which means they'll get a years worth of funding.
why isn't big pharma taking a stake for this small amount of money? thats the worry i have.
Pat, not sure, but I suspect that was the banker/wanker...
Glad he's learned to type (though I realize he needs to protect those knuckles for dragging-upon)!
yep thats me - joshi
Post a Comment